메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Boehringer Ingelheim and Simcere partner to advance a du…

[ 메디채널 김갑성 기자 ] Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million SHANGHAI, Jan. 27, 2026 -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a
- 김갑성 기자
- 2026-01-27 18:40
Libevitug Approved in China as First-in-Class Treatment for H…

BEIJING, Jan. 27, 2026 -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for vir
- 김갑성 기자
- 2026-01-27 16:18
Libevitug Approved in China as First-in-Class Hepatitis D Trea…

BEIJING, Jan. 27, 2026 -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus (HBV) and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China's first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clini
- 김갑성 기자
- 2026-01-27 16:15
Servier delivers solid performance in 2024/25 and confirms its f…

Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. Growth over the financial year was driven by increased sales in oncology, particularly in the United States. Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group's ambitions for 2030. SURESNES, France, Jan. 27, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, published its financi
- 김갑성 기자
- 2026-01-27 16:00
3Shape appoints Rasmus Hannemann as Senior Vice Pres…

COPENHAGEN, Denmark, Jan. 27, 2026 -- 3Shape today announced the appointment of Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy, effective 9 March. Rasmus will step into the Senior Leadership Team and will report directly to CEO Jacob Paulsen. Rasmus joins 3Shape from Coloplast, where he spent more than 20 years in senior leadership roles spanning strategy, product management, marketing, and global business leadership. Most recently, he served as Vice President, Group Development & Strategy, with responsibility for corporate strategy, M&A, and post-m
- 김갑성 기자
- 2026-01-27 15:45
Getinge Q4 and Full-Year Report 2025: Organic growth and so…

GOTHENBURG, Sweden, Jan. 27, 2026 -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge. Higher demand for consumables for ECLS-therapy in the quarter and in Acute Care Therapies contributed to Getinge's performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general
- 김갑성 기자
- 2026-01-27 15:23
Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam an…

DAVOS, Switzerland, Jan. 27, 2026 -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, the Ministry of Health of Brunei Darussalam, and EVYD Technology will jointly implement an AI- and data-enabled national cardiovascular disease prevention initiative under the global program: CARDIO4Cities. Built on Brunei's national health platform, the program aims to harness population-scale data and artificial intelligence to enable early identification of high
- 김갑성 기자
- 2026-01-27 14:37
Swan Defence and Heavy Industries Limited、欧州のRederiet St…

インド、ムンバイ, 2026年1月27日 -- Swan Defence and Heavy Industries Limited（SDHI）は大きな節目を迎え、再度活気を取り戻したインド、グジャラート州の造船所にて、IMO Type IIのケミカルタンカー6隻（各載貨重量トン数：1万8000トン）の初の新造船契約を締結したと発表しました。 2億2,700万米ドルに上るこの契約は欧州の大手船主である Rederiet Stenersen AS によるもので、インドの造船所が受注したケミカルタンカーとしては最大規模になります。この契約により、世界規模の複雑な商業運送船を建造するSDHIの能力が再度証明されました。この契約には、さらに6隻の姉妹艦が含まれています。最初の船は33ヶ月以内に引き渡される予定で、その後も一定の間隔で引き渡しが予定されています。本船は、 Marinform AS および StoGda Ship Design & Engineeringが設計を担当し、 DNVによってクラス分けされます。このタンカーは、 Ice Class 1A 基準で建造され、高度なデュアルフューエルのLNG対応ハイブリッド推進を特徴とし、高度な自動化をはじめとする複数の運航モードを可能にします。 SDHI
- 김갑성 기자
- 2026-01-27 13:15
스완 디펜스 앤드 헤비 인더스트리즈, 유럽의 레데리엣 스테네르센으로부터 화학제품 운반선…

뭄바이, 인도, 2026년 1월 27일 -- 스완 디펜스 앤드 헤비 인더스트리즈(Swan Defence and Heavy Industries Limited, SDHI)가 인도 구자라트주에 위치한 자사의 현대화된 조선소에서 건조될 1만 8000 DWT급 IMO Type II 화학제품 운반선 6척에 대한 첫 신조 계약을 체결하며 중대한 이정표를 세웠다고 발표했다. 이번 계약은 유럽의 주요 선주사인 레데리엣 스테네르센(Rederiet Stenersen AS)으로부터 수주한 것으로, 계약 금액은 미화 2억 2700만 달러에 달한다. 이는 인도 조선소가 수주한 화학제품 운반선 프로젝트 중 최초이자 최대 규모로, SDHI가 고난도의 세계적 수준 상선 건조 역량을 갖추고 있음을 다시 한번 입증하는 성과다. 계약에는 동일 선형의 추가 6척에 대한 옵션도 포함돼 있다. 첫 번째 선박은 계약 체결 후 33개월 이내 인도될 예정이며, 이후 선박들은 일정한 간격을 두고 순차적으로 인도된다. 해당 선박은 마린폼(Marinform AS)과 스토그다 쉽 디자인 & 엔지니어링(StoGda Ship Design & Eng
- 김갑성 기자
- 2026-01-27 13:13
Nuance Pharma Announces Acceptance for Review of the N…

SHANGHAI, Jan. 27, 2026 -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease. Ohtuvayre® is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3 and PDE4") that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer.&nbs
- 김갑성 기자
- 2026-01-27 10:13

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분